Life Sciences Tools and Services
Company Overview of Metamark Genetics, Inc.
Metamark Genetics, Inc., a biotechnology company, develops function-based, prognostic and diagnostic tests focusing on enhancing cancer care. The company’s genomic and proteomic discovery platforms develop solutions for various disease areas, such as prostate, bladder, colon, and breast cancers. It also provides specialty urological pathology testing services comprising prostate biopsy; triple stain; assessment of loss of PTEN function; ProMark, a prostate cancer prognostic test that differentiates indolent from aggressive disease; urine cytology; FISH molecular cytology; and other uropathology services to urologists, pathologists, and their patients in the United States. In addition, the co...
245 First Street
Cambridge, MA 02142
Founded in 2007
Key Executives for Metamark Genetics, Inc.
Chief Executive Officer, President and Director
Co-Founder, Director and Scientific & Clinical Advisor
Co-Founder, Consultant and Scientific & Clinical Advisor
Senior Vice President of Clinical Operations
Compensation as of Fiscal Year 2015.
Metamark Genetics, Inc. Key Developments
Metamark Appoints Jerome Richie as Chief Medical Officer, Effective July 1, 2015
Jun 23 15
Metamark has appointed Dr. Jerome Richie as its chief medical officer. Richie will join the leadership team effective July 1, retiring from his current role of chief emeritus of Harvard program in Urology at Brigham and Women's Hospital and a surgery professor at Harvard Medical School.
Metamark Appoints Jerome P. Richie, M.D. as Chief Medical Officer, Effective July 1, 2015
May 14 15
Metamark announced that Jerome P. Richie, M.D. will join company's executive leadership team as Chief Medical Officer, effective July 1, 2015. Dr. Richie will retire from his current roles, which he has held since 1987, as the Chief (Emeritus) of the Harvard Program in Urology (Longwood Area) at Brigham and Women's Hospital in Boston, as well as the Elliott Carr Cutler Professor of Surgery (Urology) at Harvard Medical School, on June 30. Beginning on July 1, Dr. Richie will head Metamark’s clinical development and medical affairs.
Metamark Announces Partnership with Highmark Blue Shield to Provide Access to Comprehensive Urology Diagnostics
Apr 21 15
Metamark announced that it has signed an agreement with Highmark Blue Shield to provide its 5.2 million members with in-network access to Metamark’s comprehensive suite of urology specialized diagnostic offerings. The agreement covers Highmark Blue Shield members in Delaware, Pennsylvania and West Virginia. Metamark provides access to sophisticated diagnostic and prognostic tools that enable urologists to chart their patient’s optimal treatment path throughout the continuum of prostate care.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|